February 3, 2026 Rocatinlimab Demonstrates Significant Efficacy and Safety in Phase 3 Trials for Moderate-to-Severe Atopic Dermatitis
/department-of-communications-(dco)/digital-social-visual-(dsv)/who-logo-at-headquarters.tmb-1200v.jpg?sfvrsn=34ba81d2_1){kind=logo}
